Cardiac safety remains the leading cause of drug development discontinuation. AnaBios has developed a human cardiomyocyte-based model that has the potential to provide a predictive preclinical approach for simultaneously predicting drug-induced inotropic and pro-arrhythmia risk. The human ventricular trabeculae-based model can clearly differentiate between pro-arrhythmia and non-proarrhythmic drugs and has the potential to enable a generation of reliable and predictive human-based cardiotoxicity data at the pre-clinical stage.

AUTHORS: Najah Abi-Gerges, Ashley Alamillo, Phachareeya Ratchada, Guy Page, Yannick Miron, Nathalie Nguyen, Paul E Miller and Andre Ghetti